New drug combo shows promise for tough ovarian cancer
NCT ID NCT05296512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, pembrolizumab and lenvatinib, in 30 people with recurrent clear cell ovarian cancer. The goal is to see if the combination can shrink tumors or slow cancer growth. Participants must have had at least one prior treatment and have measurable disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota, 55905, United States
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a personalized exercise program boost recovery in cancer survivors?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a pill target Hard-to-Treat ovarian cancers?
- Can a smart drug missile take down a tough ovarian cancer?
- Braids and conditioner may boost scalp cooling against chemo hair loss
- New imaging tool could help surgeons detect hidden cancer cells during surgery